Daniel Pearlstein was named associate director, corporate strategy, of POINT Biopharma (NASDAQ:PNT), which debuted on the Nasdaq Capital Market on July 1, 2021.
Mr. Pearlstein was formerly EVP for strategy with Canopy Rivers, the venture capital arm of Canopy Growth. Before that, he was a healthcare equity analyst at Eight Capital, M Partners and Lumira Capital.
POINT Biopharma, a radiopharmaceuticals company, has completed enrollment and initial dosing of a 25-patient safety and dosimetry lead-in of its Phase 3 SPLASH study evaluating PNT2002 for the treatment of metastatic castration-resistant prostate cancer.
